로딩 중…
StockDiggingStockDigging

LivaNova PLC

LIVN· NASDAQ
GBGB
$78.01+0.28%
2026-09-18

Financials

Valuation Metrics

LivaNova PLC's Market Cap is $4.29B. At end of 2025 it was $3.35B. Ranked #1473 of 3,121 in US market (top 47%), #510 of 1,463 on NASDAQ (top 35%), #92 of 205 in Health Care Equipment & Services (top 45%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$4.29B
Revenue$1.47B
Net Income$189M
Total Assets$2.64B
Net Assets$1.33B
Employees3,300
Value
P/E22.72x
P/B3.23x
P/S2.91x
EV/EBITDA22.80x
FCF Yield3.46%
Profitability
ROE14.23%
ROA7.14%
Op. Margin13.48%
Revenue Growth12.39%
Financial Health
Debt Ratio99.26%
Total Debt$352M
FCF$148M
Cash$517M
Current Ratio1.45x
Net Debt/EBITDA-0.91x
Performance
1Y Return39.53%
1M Return-3.50%
From 52W High-9.04%
1Y MDD-18.89%
Trading
Volume511,293 shares
Trading Value$40M
Per Share
EPS$3.43
BPS$24.13

Company Info

CEO Mr. Vladimir A. Makatsaria
Employees 3,300
HQ London, United Kingdom

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.